{"nctId":"NCT01000974","briefTitle":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","startDateStruct":{"date":"2010-06-18"},"conditions":["Haemophilus Influenzae Type b"],"count":4003,"armGroups":[{"label":"Hiberix Group","type":"EXPERIMENTAL","interventionNames":["Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)","Biological: Pediarix™","Biological: Prevnar 13™","Biological: Rotarix™","Biological: Infanrix™"]},{"label":"ActHIB Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ActHIB™","Biological: Pediarix™","Biological: Prevnar 13™","Biological: Rotarix™","Biological: Infanrix™"]},{"label":"Pentacel Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Pentacel™","Biological: Prevnar 13™","Biological: Rotarix™","Biological: Engerix™-B"]}],"interventions":[{"name":"GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)","otherNames":["Hiberix®"]},{"name":"ActHIB™","otherNames":[]},{"name":"Pentacel™","otherNames":[]},{"name":"Pediarix™","otherNames":[]},{"name":"Prevnar 13™","otherNames":[]},{"name":"Rotarix™","otherNames":[]},{"name":"Engerix™-B","otherNames":[]},{"name":"Infanrix™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects for whom the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR\\[s\\]) can and will comply with the requirements of the protocol (e.g., completion of the diary card, return for follow-up visits).\n* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.\n* Written informed consent obtained from the subject's parent/LAR.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Born after a gestation period of minimum 36 weeks.\n* Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrollment.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* Planned administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine and until 30 days after the booster dose.\n* Previous vaccination against Haemophilus influenzae type b, diphtheria, tetanus, pertussis, Pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.\n* History of Haemophilus influenzae type b, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus, and hepatitis B diseases.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including dry natural latex rubber.\n* Major congenital defects or serious chronic illness.\n* History of any neurologic disorders or seizures.\n* Acute disease at time of enrollment. All vaccines can be administered to persons with a minor illness.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.\n* Concurrent participation in another clinical study, up to 30 days prior to study entry or at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Child in care.\n* History of intussusception.\n* History of uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.\n* History of Severe Combined Immunodeficiency Disease.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL","description":"Non-inferiority of Hiberix to ActHIB, each co-administered with Pediarix, Prevnar13 and Rotarix following 3 primary doses in terms of immune response to PRP (Anti-PRP≥ 0.15 µ g/ml and ≥1.0 µg/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1536","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"234","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1291","spread":null},{"groupId":"OG001","value":"246","spread":null},{"groupId":"OG002","value":"198","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)","description":"Non-inferiority of Pediarix co-administered with Hiberix, Prevnar13 and Rotarix compared to Pediarix co-administered with ActHIB, Prevnar13 and Rotarix following 3 primary vaccine doses in terms of immune response to Diphtheria, Tetanus.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"273","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"274","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations","description":"Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.193","spread":null},{"groupId":"OG001","value":"6.743","spread":null},{"groupId":"OG002","value":"3.640","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody Concentrations","description":"Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"71.9","spread":null},{"groupId":"OG002","value":"41.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.6","spread":null},{"groupId":"OG001","value":"93.5","spread":null},{"groupId":"OG002","value":"51.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"321.8","spread":null},{"groupId":"OG001","value":"295.8","spread":null},{"groupId":"OG002","value":"174.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody Concentrations","description":"Antibody concentrations against S.pneumoniae were given as geometric mean concentrations (GMCs) expressed as microgram per milliliter (µg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.515","spread":null},{"groupId":"OG001","value":"2.500","spread":null},{"groupId":"OG002","value":"2.442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.056","spread":null},{"groupId":"OG001","value":"1.008","spread":null},{"groupId":"OG002","value":"1.190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.804","spread":null},{"groupId":"OG001","value":"1.803","spread":null},{"groupId":"OG002","value":"1.819","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.729","spread":null},{"groupId":"OG001","value":"3.656","spread":null},{"groupId":"OG002","value":"3.530","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.442","spread":null},{"groupId":"OG001","value":"3.340","spread":null},{"groupId":"OG002","value":"3.384","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.065","spread":null},{"groupId":"OG001","value":"0.994","spread":null},{"groupId":"OG002","value":"0.875","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.518","spread":null},{"groupId":"OG001","value":"4.115","spread":null},{"groupId":"OG002","value":"3.785","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.516","spread":null},{"groupId":"OG001","value":"2.431","spread":null},{"groupId":"OG002","value":"2.226","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.506","spread":null},{"groupId":"OG001","value":"4.111","spread":null},{"groupId":"OG002","value":"3.938","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.655","spread":null},{"groupId":"OG001","value":"3.507","spread":null},{"groupId":"OG002","value":"3.401","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.556","spread":null},{"groupId":"OG001","value":"1.553","spread":null},{"groupId":"OG002","value":"1.321","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.745","spread":null},{"groupId":"OG001","value":"2.833","spread":null},{"groupId":"OG002","value":"2.531","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.046","spread":null},{"groupId":"OG001","value":"1.985","spread":null},{"groupId":"OG002","value":"1.670","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)","description":"Seroresponse (95%) was defined as the number of subjects showing a concentration above a threshold that leads to 95% seroresponse in the ActHIB group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"764","spread":null},{"groupId":"OG001","value":"264","spread":null},{"groupId":"OG002","value":"201","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"762","spread":null},{"groupId":"OG001","value":"262","spread":null},{"groupId":"OG002","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"744","spread":null},{"groupId":"OG001","value":"263","spread":null},{"groupId":"OG002","value":"191","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off Value","description":"The cut-off value was defined as a concentration ≥ 8 ED50 (ED50 is the concentration at which the protein exhibits 50% of its maximum activity).\n\nThe polio testing which started at the Biomnis laboratory was stopped because the polio virus micro-neutralization assays were found to be not in line with the quality standards defined in GSK Biologicals' SOPs. As a result, polio testing was restarted at the GSK laboratory and the results were uploaded into the clinical database.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"181","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"188","spread":null},{"groupId":"OG002","value":"183","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"254","spread":null},{"groupId":"OG001","value":"181","spread":null},{"groupId":"OG002","value":"168","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL","description":"Non-inferiority of a booster dose of Hiberix co-administered with Infanrix in subjects 15-18 months of age who received 3 primary vaccine doses of Hiberix to a booster dose of ActHIB co-administered with Infanrix in subjects of 15-18 months of age who received 3 primary vaccine doses of ActHIB in terms of immune response to PRP","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"231","spread":null},{"groupId":"OG002","value":"184","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-protein-D (Anti-D) and Anti-protein-T (Anti-T) Antibody Concentrations","description":"Antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as International Units per milliliter (IU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":null},{"groupId":"OG001","value":"2.45","spread":null},{"groupId":"OG002","value":"1.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":null},{"groupId":"OG001","value":"2.44","spread":null},{"groupId":"OG002","value":"1.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1932","spread":null},{"groupId":"OG001","value":"366","spread":null},{"groupId":"OG002","value":"370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1165","spread":null},{"groupId":"OG001","value":"233","spread":null},{"groupId":"OG002","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"834","spread":null},{"groupId":"OG001","value":"174","spread":null},{"groupId":"OG002","value":"195","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Rectal temperature equal to or above (≥) 38 degrees Celsius (°C).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2179","spread":null},{"groupId":"OG001","value":"398","spread":null},{"groupId":"OG002","value":"378","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2478","spread":null},{"groupId":"OG001","value":"449","spread":null},{"groupId":"OG002","value":"434","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1450","spread":null},{"groupId":"OG001","value":"275","spread":null},{"groupId":"OG002","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1014","spread":null},{"groupId":"OG001","value":"186","spread":null},{"groupId":"OG002","value":"143","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1880","spread":null},{"groupId":"OG001","value":"350","spread":null},{"groupId":"OG002","value":"324","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With AEs of Specific Interest (AESIs)","description":"An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Seroresponse (90%) to Anti-PT, Anti-PRN and Anti-FHA","description":"Seroresponse (90%) was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"706","spread":null},{"groupId":"OG001","value":"248","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"741","spread":null},{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"705","spread":null},{"groupId":"OG001","value":"248","spread":null},{"groupId":"OG002","value":"166","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PT, Anti-PRN and Anti-FHA Antibody Concentrations ≥ 5 EL.U/mL","description":"Seroresponse was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"789","spread":null},{"groupId":"OG001","value":"275","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"786","spread":null},{"groupId":"OG001","value":"275","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"791","spread":null},{"groupId":"OG001","value":"275","spread":null},{"groupId":"OG002","value":"249","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL","description":"Evaluation of persistence of anti-PRP antibodies induced by three primary vaccine doses of Hiberix, and ActHIB, each co-administered with Pediarix, Prevnar 13 and Rotarix, or Pentacel co-administered with Engerix-B, Rotarix and Prevnar 13 prior to the booster dose of Hiberix, ActHIB or Pentacel at 15-18 months of age and evaluation of immunogenicity of a booster dose of Hiberix co-administered with Infanrix, ActHIB co-administered with Infanrix and Pentacel in terms of the percentage of subjects with anti-PRP concentrations ≥0.15 µg/mL, ≥1.0 µg/mL and GMCs one month after the booster dose.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":null},{"groupId":"OG001","value":"172","spread":null},{"groupId":"OG002","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"235","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"231","spread":null},{"groupId":"OG002","value":"184","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Hepatitis B (Anti-HBs) Antibody Concentrations","description":"Antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressedas milli-international units per milliliter (mIU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3684.3","spread":null},{"groupId":"OG001","value":"3545.6","spread":null},{"groupId":"OG002","value":"1573.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With S.Pneumoniae Antibody Concentrations ≥ 0.05 µg/mL, ≥ 0.2 µg/mL and ≥1.0 µg/mL","description":"Evaluation of immunogenicity of a 3-dose primary vaccination course of Prevnar 13 co-administered with Hiberix, Rotarix and Pediarix, of Prevnar 13 co-administered with ActHIB, Rotarix and Pediarix and of Prevnar 13 co-administered with Pentacel, Rotarix and Engerix-B in terms of S.pneumoniae GMCs and antibody concentrations ≥ 0.05µg/mL, ≥ 0.2 µg/mL, ≥ 1.0 µg/mL at one month after the last dose of primary vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"384","spread":null},{"groupId":"OG001","value":"268","spread":null},{"groupId":"OG002","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"268","spread":null},{"groupId":"OG002","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"266","spread":null},{"groupId":"OG002","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"378","spread":null},{"groupId":"OG001","value":"260","spread":null},{"groupId":"OG002","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"385","spread":null},{"groupId":"OG001","value":"270","spread":null},{"groupId":"OG002","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"384","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"380","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"383","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"384","spread":null},{"groupId":"OG001","value":"268","spread":null},{"groupId":"OG002","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"384","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"268","spread":null},{"groupId":"OG002","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"377","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"351","spread":null},{"groupId":"OG001","value":"242","spread":null},{"groupId":"OG002","value":"224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"385","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"377","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"259","spread":null},{"groupId":"OG002","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"383","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"376","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null},{"groupId":"OG001","value":"239","spread":null},{"groupId":"OG002","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"226","spread":null},{"groupId":"OG002","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354","spread":null},{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"357","spread":null},{"groupId":"OG001","value":"253","spread":null},{"groupId":"OG002","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"151","spread":null},{"groupId":"OG002","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"264","spread":null},{"groupId":"OG002","value":"239","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"234","spread":null},{"groupId":"OG002","value":"203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"360","spread":null},{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"223","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"361","spread":null},{"groupId":"OG001","value":"256","spread":null},{"groupId":"OG002","value":"229","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"200","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"357","spread":null},{"groupId":"OG001","value":"254","spread":null},{"groupId":"OG002","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"208","spread":null},{"groupId":"OG002","value":"180","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Titers for Poliovirus Types 1, 2 and 3","description":"Antibody titers were given as geometric mean titers(GMTs).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"570.8","spread":null},{"groupId":"OG001","value":"620.9","spread":null},{"groupId":"OG002","value":"136.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"471.8","spread":null},{"groupId":"OG001","value":"389.9","spread":null},{"groupId":"OG002","value":"210.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"982.8","spread":null},{"groupId":"OG001","value":"963.2","spread":null},{"groupId":"OG002","value":"297.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-HBs Antibody Concentrations Greater Than or Equal to Cut-off Values","description":"The cut-off values were defined as a concentration≥ 3.3 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"362","spread":null},{"groupId":"OG001","value":"257","spread":null},{"groupId":"OG002","value":"239","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"362","spread":null},{"groupId":"OG001","value":"257","spread":null},{"groupId":"OG002","value":"239","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-polyribosylribitol Phosphate (PRP) Antibody Concentrations","description":"Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.498","spread":null},{"groupId":"OG001","value":"0.467","spread":null},{"groupId":"OG002","value":"0.380","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.782","spread":null},{"groupId":"OG001","value":"40.293","spread":null},{"groupId":"OG002","value":"37.543","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL","description":"Antibody concentrations were expressed as geometric mean concentrations (GMCs) and expressed as milli-international units per milliliter (mIU/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"268.3","spread":null},{"groupId":"OG001","value":"247.0","spread":null},{"groupId":"OG002","value":"156.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-HB Antibody Concentrations ≥10.0 mlU/mL and ≥6.2mLU/mL","description":"The cut-off values were defined as a concentration≥ 6.2 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"311","spread":null},{"groupId":"OG001","value":"199","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":null},{"groupId":"OG001","value":"198","spread":null},{"groupId":"OG002","value":"154","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations ≥ 5 EL.U/mL","description":"Evaluation of persistence of anti-PT, anti-FHA and anti-PRN antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-PT, anti-FHA and anti- PRN antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"328","spread":null},{"groupId":"OG001","value":"223","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"235","spread":null},{"groupId":"OG002","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null},{"groupId":"OG001","value":"174","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"331","spread":null},{"groupId":"OG001","value":"233","spread":null},{"groupId":"OG002","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"168","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"335","spread":null},{"groupId":"OG001","value":"235","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-poliovirus Types 1, 2, and 3 Antibody Titres and Titres ≥ 8","description":"Antibody concentrations were tabulated as geometric mean titers (GMTs) and expressed as titers.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106.2","spread":null},{"groupId":"OG001","value":"101.6","spread":null},{"groupId":"OG002","value":"25.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.4","spread":null},{"groupId":"OG001","value":"89.5","spread":null},{"groupId":"OG002","value":"48.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154.8","spread":null},{"groupId":"OG001","value":"151.9","spread":null},{"groupId":"OG002","value":"40.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-Polio-1,2,3 Antibody Titers ≥ 8","description":"Anti-polio 1,2,3 antibody titers greater or equal to the cut off value were calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"294","spread":null},{"groupId":"OG001","value":"197","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"196","spread":null},{"groupId":"OG002","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"283","spread":null},{"groupId":"OG001","value":"201","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-D and Anti-T Antibody Concentrations ≥ 0.1 IU/mL and ≥1.0 IU/mL, Respectively.","description":"Evaluation of persistence of anti-D, anti-T antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-D and anti-T antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322","spread":null},{"groupId":"OG001","value":"218","spread":null},{"groupId":"OG002","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"236","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"196","spread":null},{"groupId":"OG002","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"336","spread":null},{"groupId":"OG001","value":"236","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null},{"groupId":"OG001","value":"234","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"233","spread":null},{"groupId":"OG002","value":"180","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"918","spread":null},{"groupId":"OG001","value":"179","spread":null},{"groupId":"OG002","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"659","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Axillary temperature equal to or above (≥) 38 degrees Celsius (°C).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"857","spread":null},{"groupId":"OG001","value":"164","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1293","spread":null},{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"201","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"614","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With AEs of Specific Interest (AESIs)","description":"An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"882","spread":null},{"groupId":"OG001","value":"159","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-FHA, Anti-PRN and Anti-PT Antibody Concentrations","description":"Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"464.9","spread":null},{"groupId":"OG001","value":"492.5","spread":null},{"groupId":"OG002","value":"263.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"11.2","spread":null},{"groupId":"OG002","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"288.9","spread":null},{"groupId":"OG001","value":"259.2","spread":null},{"groupId":"OG002","value":"153.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"8.6","spread":null},{"groupId":"OG002","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"93.1","spread":null},{"groupId":"OG002","value":"75.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":120,"n":2963},"commonTop":["Irritability","Somnolence","Pain","Decreased appetite","Erythema"]}}}